Panacea Life Sciences Holdings, Inc.

PLSHOTCHealthcare● Active

$0.03

+$0.00(+0.00%)

Market Cap$679161

P/E Ratio—

52W High$0.1996

52W Low$0.0211

Avg Volume16K

Open$0.03

Beta2.68

Free Cash Flow Financials Revenue

Panacea Life Sciences Holdings, Inc. (PLSH) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

PLSH · free cash flow · updated Jun 15, 2026

Core FCF metrics

PLSH · FCF · TTM · margin & CAGR

Free cash flow was $617,480 for FY2025 (fiscal year ending 2025-12-31), down 10.4% year-over-year The FCF margin was 67.8%.

FY2025 Free Cash Flow$617,480▼ -10.4% YoY

Trailing 12M (TTM)−$8,809Trailing 4Q sum · TTM negative vs latest FY positive

FCF Margin67.8%$617,480 ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 15, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

PLSH · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$617,478(0M)$617,480▼ 10.4%67.8%

FY2024$688,865(0M)$688,860▲ +143.3%16.8%

FY2023−$1.5M(0M)−$1.6M▲ +39.9%-66.7%

FY2022−$2.4M(0M)−$2.6M▲ +35.3%-162.5%

FY2021−$3.9M(0M)−$4.1M▲ +62.3%-198.3%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

PLSH · P/FCF · FCF yield · FCF per share

Panacea Life Sciences Holdings, Inc. (PLSH) valuation ratios are currently unavailable — market cap, share count, or TTM data could not be retrieved from our data provider.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

Valuation ratios are unavailable — market cap, share count, or TTM data could not be retrieved. Individual metrics are shown where available.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

PLSH · cash flow statement · operating / investing / financing

For FY2025, Panacea Life Sciences Holdings, Inc. generated $0.6M in operating cash flow and spent 0M in capital expenditures, yielding $0.6M in free cash flow.

Operating Activities

+$0.6M

Cash from core business operations

2025-12-31

Investing Activities

−$0.1M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

−$2.0M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF ($0.6M) − |CapEx| (0M) = FCF ($0.6M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

PLSH vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Panacea Life Sciences Holdings, Inc.YOU

PLSH

$617,480-10.4%67.8%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Panacea Life Sciences Holdings, Inc. (PLSH) reported free cash flow of $617,480 for FY2025 (fiscal year ending 2025-12-31), down 10.4% year-over-year. The FCF margin was 67.8%.

Based on available data, Panacea Life Sciences Holdings, Inc. has maintained positive free cash flow for at least 2 fiscal year(s). FCF peaked at $688,860 in FY2024.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

PLSH free cash flow · 8 questions

Panacea Life Sciences Holdings, Inc. free cash flow was $617,480 for FY2025, down 10.4% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$8,809.

PLSH free cash flowPLSH FCFPLSH FCF 2025PLSH free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Panacea Life Sciences Holdings, Inc. · Panacea Life Sciences Holdings, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 15, 2026